Navigation Links
BD to Increase Access to Vital Cervical Cancer Screening in Resource-Limited Settings Through Commitment to Pink Ribbon Red Ribbon Initiative®
Date:9/13/2011

FRANKLIN LAKES, N.J., Sept. 13, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a commitment to Pink Ribbon Red Ribbon®, an innovative initiative to leverage public and private investments in global health to combat cervical and breast cancer led by the George W. Bush Institute, the President's Emergency Plan for AIDS Relief (PEPFAR), Susan G. Komen for the Cure, and the Joint United Nations Programme on HIV/AIDS (UNAIDS).

BD's commitment to Pink Ribbon Red Ribbon is to help achieve widespread, sustainable access to state-of-the-art cervical cancer diagnostic technology for women in countries currently supported by PEPFAR.  To accomplish this goal, BD will provide deeply discounted pricing on its vital cervical cancer diagnostic tests in these developing and emerging countries.  This discount translates to approximately 10 million dollars for every one million women that are screened.  

To help strengthen the technical capabilities on the ground, BD will provide education and training for laboratory staff and healthcare workers on screening for cervical cancer. BD will also collaborate with the Pink Ribbon Red Ribbon initiative participants to develop in-country guidelines and policies for effective cervical cancer screening.

"We're grateful for BD's commitment and investment in the Pink Ribbon Red Ribbon initiative," said Eric Bing, Senior Fellow and Director of Global Health at the George W. Bush Institute. "Our goal is to reduce deaths from cervical cancer by an estimated 25% among women screened and treated through the initiative, significantly increase access to cervical cancer prevention, diagnosis and treatment and breast cancer awareness programs, and create innovative models that can be scaled up and used globally. Our founding corporate partner's generosity and commitment to saving lives is a critical part of ensuring we meet these goals."

"BD shares a common goal with The George W. Bush Institute, UNAIDS and the United States Government to leverage the world's investment and experience in HIV to strengthen the response to non-communicable diseases, beginning with cervical cancer," said Vincent A. Forlenza, President and Chief Operating Officer, BD.  "To help save the lives of millions of women and girls, BD is committed to deploying our advanced technologies and capabilities to enable effective cervical cancer screening worldwide."

Cervical cancer is the leading cause of death among young women in developing countries.  It is the most common women's cancer in Africa and is the third most common cancer in women, affecting 529,000 women and killing 275,000 women each year. In some parts of Latin America, cervical cancer diagnosis and death rates rival those seen in Africa. More than 85 percent of the global burden of cervical cancer occurs in developing countries, where it accounts for 13 percent of all female cancers, yet fewer than 5 percent of women have access to screening even once in a lifetime. (SOURCE: PRRR)

BD's cervical cancer diagnostic technologies utilize liquid-based cytology, a method of preparing cervical cells for examination in a laboratory. The centrifuging process in liquid-based cytology allows for clearer, more uniform samples that are easier for laboratory staff to analyze. This also helps reduce the number of unreadable or inconclusive tests, requiring fewer women to return to clinics for repeat testing.

About Pink Ribbon Red Ribbon

Pink Ribbon Red Ribbon is an innovative initiative to leverage public and private investments in global health to combat cervical and breast cancer – two of the leading causes of cancer death in women – in Sub-Saharan Africa and Latin America.   Led by the George W. Bush Institute, the President's Emergency Plan for AIDS Relief (PEPFAR), Susan G. Komen for the Cure, and the Joint United Nations Programme on HIV/AIDS (UNAIDS), Pink Ribbon Red Ribbon will expand the availability of vital cervical cancer screening and treatment and breast care education – especially for women most at risk in developing nations because they have HIV.

The initiative will leverage the platform and resources of the U.S. President's Emergency Plan for AIDS Relief's (PEPFAR) care model – established under President Bush and a cornerstone of President Obama's Global Health Initiative (GHI) – and will draw from lessons learned in the significant scaling-up of access to HIV services in recent years.

With initial commitments of $80 million across 5 years, Pink Ribbon will expand to achieve the goals of reducing deaths from cervical cancer by an estimated 25% among women screened and treated through the initiative, significantly increase access to breast and cervical cancer prevention, diagnosis and treatment programs, and create innovative models that can be scaled up and used globally.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world.  BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

Contact: Alyssa Zeff
BD Public Relations
(201) 847-4358
Alyssa_Zeff@bd.com


'/>"/>
SOURCE BD (Becton, Dickinson and Company)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
2. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
3. Seriously Low Vaccination Rates Cause Experts to Call for Increased Immunization Before Influenza Season Peaks
4. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
5. Demand for VScan Dengue Fever Test Kits Increases
6. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
7. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
8. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
9. Superbug Outbreak Calls for Immediate Increased Attention on Infection Control
10. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
11. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... 2016 TARE (Transarterial Radio-embolization) ... Savings and Overall Decreased Use of Hospital ... international specialist healthcare company, has today announced the ... Meeting of ISPOR (International Society for Pharmacoeconomics and ... (HCC) using yttrium-90 glass microspheres is associated with ...
(Date:5/25/2016)... FDA 510(k) clearance covers ... for urological and surgical applications Mauna ... Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) platform, ... US with the 12 th 510(k) clearance ... This new FDA clearance covers Confocal Miniprobes indicated ...
(Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 27, 2016 , ... An educational campaign aimed at everyone ... courtesy of awareness-driven celebrities and thought leaders. It also provides insight to the ... leaders such as Bioness. , As patients feel increasingly concerned about the ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... Aimed at ... human interest stories, which come courtesy of leaders in the nursing and health care ... from leading advocates and associations—namely Abilene Christian University. , As the nursing industry ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways to cook a ... (NHDSC) suggests that Americans prefer their dogs straight off the grill. Of the 90 ... their favorite way to cook a hot dog, far outpacing other cooking methods such ...
(Date:5/26/2016)... Atlanta, Georgia (PRWEB) , ... May 26, 2016 ... ... a certificate in intellectual property (IP) to its specialty academic programs. , Answering ... joins the college’s existing certificate programs in health law, and environmental and land ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... a significant negative impact on long-term patient survival, reports a team of UPMC ... online this week in the Journal of Thoracic and Cardiovascular Surgery, provide critical ...
Breaking Medicine News(10 mins):